EuroBiotech: More Articles of Note


> The FDA accepted MorphoSys’ application for approval of tafasitamab for priority review. The agency is due to make a decision about the drug by the end of August. Release 

> Nordic Nanovector revealed it has enrolled 47 of a targeted 130 patients in its pivotal follicular lymphoma trial. The company has opened new sites to accelerate enrollment but is yet to see a big impact on the recruitment rate. Statement 

> Mereo BioPharma set out the work it plans to do to support FDA approval of its treatment for osteogenesis imperfecta. The strategy centers on a single study in around 160 subjects. Release 

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

> Debiopharm began a phase 1 trial of WEE-1 inhibitor Debio 0123. The Swiss biotech is developing the drug as a treatment for advanced solid tumors. Statement 

> Cinclus Pharma raised SEK 250 million ($26 million) to take X842 to phase 3. The molecule in X842, linaprazan, underwent clinical testing at AstraZeneca before being dropped in response to weak data. Release 

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.